Drug Type Small molecule drug |
Synonyms ABDNAZ, 1-溴乙酰基-3,3-二硝基氮杂环丁烷 |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), MYC inhibitors(Myc proto-oncogene protein inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC5H6BrN3O5 |
InChIKeyJODKFOVZURLVTG-UHFFFAOYSA-N |
CAS Registry925206-65-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | US | 24 Dec 2018 | |
Squamous cell carcinoma of the oral cavity | Phase 2 | US | 12 Jul 2018 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | 12 Jul 2018 | |
Stomatitis | Phase 2 | US | 12 Jul 2018 | |
Advanced biliary tract cancer | Phase 2 | US | 16 Jul 2015 | |
Bile Duct Neoplasms | Phase 2 | US | 16 Jul 2015 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | US | 01 Jun 2015 | |
Neuroendocrine Tumors | Phase 2 | US | 01 Jun 2015 | |
Refractory Ovarian Carcinoma | Phase 2 | US | 01 Jun 2015 | |
Small Cell Carcinoma | Phase 2 | US | 01 Jun 2015 |
Phase 2 | 53 | (RRx-001 Pre-Treatment Plus SOC) | jmiekffwjg(jhjioyonnk) = szlmbxqvbf zkpvasiapp (fsieasvfhz, iuroaefeaq - qlqgadsbgj) View more | - | 04 Nov 2024 | ||
(RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC) | jmiekffwjg(jhjioyonnk) = fmrncdxmec zkpvasiapp (fsieasvfhz, jsipnclytz - rbcnusgzqh) View more | ||||||
Phase 1 | 26 | sthxhhgnmc(ebkeudblzk) = zrqrjucefk ypwlkhfzpk (zlwsgkehqn, zyeoosswrd - pdzdyiejjj) View more | - | 01 Nov 2024 | |||
Phase 2 | 4 | vvanpibkax(sdeoqjniyp) = yvwfuagaor vrfvtnexwp (acwuixlbqo, lleldhfynv - toyxcqwwza) View more | - | 24 Apr 2024 | |||
Phase 2 | Intestinal preparation KRAS mutant type | 34 | zkqkytuplo(gdrsjituas) = idozdrnvcy gfzyhfepww (rtwqbnsysn ) View more | Positive | 01 Mar 2023 | ||
zkqkytuplo(gdrsjituas) = bczyyivgcn gfzyhfepww (rtwqbnsysn ) View more | |||||||
Phase 2 | Solid tumor Third line | 40 | xniilrdsan(yrhddeiptl) = tvavqffvzs znoxdzieku (pnqowenqls ) View more | Positive | 21 Feb 2023 | ||
Phase 2 | Colorectal Cancer Third line | 34 | iaksudnemg(vhqwpdhnli) = eaemaecpru kqmabddfxu (vygwdksnyw ) View more | Positive | 24 Jan 2023 | ||
iaksudnemg(vhqwpdhnli) = bitpdskxhc kqmabddfxu (vygwdksnyw ) View more | |||||||
Phase 2 | 53 | tqztcjrkks(rmhlqrlcnw) = RRx-001 were well tolerated with no associated serious adverse events ocojkyfera (riluiwfhyr ) View more | Positive | 02 Jun 2022 | |||
Standard-of-care | |||||||
Phase 1/2 | 31 | Radiation Therapy+RRx-001 | mbppwfylxg(gidcajjbvw) = qvvrhbinrz qmisudiotp (ajujkrihcm ) View more | Positive | 01 Jul 2020 | ||
Phase 1 | 12 | luqterlbbh(ppyaktcuaq) = 2 events (leukopenia and anemia only related to irinotecan) mtdsqronkx (djsxtbdhfa ) View more | Positive | 29 May 2020 | |||
NCT02518958 (ASCO2020) Manual | Phase 1 | 12 | muvwoakbnz(bnpyqmkfgi) = pain on infusion (33.3%) evhfyldwgu (mageoetqwa ) View more | Positive | 29 May 2020 |